Clinical trials: Autoimmune Pulmonary Alveolar Proteinosis, open to volunteers
Autoimmune Pulmonary Alveolar Proteinosis
A Study of hBMMSC Injection in Patients With aPAP
The purpose of this multicenter, randomized, double-blind, placebo-controlled phase IIb clinical trial is to evaluate the efficacy and safety of intravenous hBMMSC injection in patients with autoimmune pulmonary alveolar…
- Trial name
- NCT07890649
- Testing
- The human Bone Marrow Mesenchymal Stem Cell (hBMMSC) injection, Lactated Ringer's Injection (crystalloid)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18.
- Trial name
- NCT06431776
- Testing
- Molgramostim
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Savara Inc.
Pulmonary Alveolar Proteinosis
Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis
This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.
- Trial name
- aPAP and GMCSF (NCT06989333)
- Testing
- GM-CSF (granulocyte-macrophage colony-stimulating factor)
- Volunteers
- 10 people
- Sponsor
- Jiuwu Bai